EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSFCAG00000013799
Gene Symbol: KCNH2
5 Cross references
253 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSFCAG00000008923
Gene Symbol: KCNQ2
5 Cross references
250 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSFCAG00000000984
Gene Symbol: KCNQ3
5 Cross references
193 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSFCAG00000024484
Gene Symbol: KCNQ5
5 Cross references
200 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSFCAG00000028093
Gene Symbol: PSEN1
5 Cross references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSFCAG00000008781
Gene Symbol: PSEN2
5 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSFCAG00000030316
Gene Symbol: PSENEN
5 Cross references
185 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSFCAG00000041663
Gene Symbol: PGR
5 Cross references
194 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSFCAG00000045717
Gene Symbol: PTGDR
5 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSFCAG00000045638
Gene Symbol: PTGDR2
5 Cross references
205 Possible Orthologues:

Prostaglandin E Receptor 1

Ensembl ID : ENSFCAG00000044590
Gene Symbol: PTGER1
5 Cross references
237 Possible Orthologues:

Prostaglandin E Receptor 3

Ensembl ID : ENSFCAG00000006185
Gene Symbol: PTGER3
5 Cross references
196 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).